T-Cell Project utilised LaRDR data for model validation
News, Newsletter June 8, 2023
Congratulations to Dr Greg Hapgood and other investigators who utilised LaRDR data in the international T-Cell Project as an external…
June 2023 newsletter arrives.
News, Newsletter June 6, 2023
Click here to read our June newsletter. Leave us a message if you would like to join the subscription list for future…
Save the date for 2023 Lymphoma Breakfast Meeting!
News, Newsletter May 26, 2023
We are pleased to announce that the hybrid Australasian Lymphoma Alliance (ALA), Lymphoma and Related Diseases Registry (LaRDR) and Lymphoma…
BLOOD abstract is due soon!
News, Newsletter May 15, 2023
Abstract submission to BLOOD 2023 is closing on 31 May 2023. If you are planning to analyse LaRDR data and submit…
April 2023 newsletter is here.
News, Newsletter April 3, 2023
Click here to read our April newsletter. Leave us a message if you would like to join the subscription list for future…
Congratulations to the ICAN project team!
News, Newsletter February 24, 2023
The ICAN Study (Immunoglobulin use and outcomes in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma) conducted by the LaRDR is closing…
6000TH PATIENT ENROLLMENT
News, Newsletter February 24, 2023
Congratulations to all participating sites at the Lymphoma and Related Diseases Registry (LaRDR) for enrolling the 6000th patient on February 24, 2023. We…
LaRDR supports Rare Disease Day 2023
News, Newsletter, Patient Experience February 16, 2023
We acknowledge the research participation and support provided by patients, carers and their clinicians. We continue to provide a national…
Older patients with classical Hodgkin lymphoma manuscript is published on Clinical Lymphoma Myeloma and Leukemia!
News, Newsletter February 10, 2023
Congratulations to Dr Zhong Goh and all contributors to the analysis of characteristics and outcomes of older patients with classical Hodgkin…
February 2023 newsletter has arrived!
News, Newsletter February 1, 2023
Click here to read our February newsletter. Leave us a message if you would like to join the subscription list for future updates.